DigiCon

@csrf

@if (isset(session()->get('doctor')['vCentralCode']))

Back

@else

@endif

Faropenem Assessment and REview of Step-down THerapy in the Management of Urinary Tract Infections (UTI) and Skin and Soft Tissue Infections (SSTI) (FRESH Study)

Doctor's details

@if (isset(session()->get('doctor')['vCentralCode']))

Name of Doctor *

@else

Name of Doctor *

@endif

Age*

@if (isset(session()->get('doctor')['vCentralCode']))

Speciality *

@else

Speciality*

@endif

General Questions

Years of Clinical Practice*

< 5 years

5-10 years

11-20 years

> 20 years

Type of Practice *

Private hospital/clinic

Government hospital/medical college

Multi-specialty hospital

Other

On an average, how many UTI cases do you treat per month? *

<20

21-30

30-50

> 50

Any other

Out of total UTI cases what is the percentage of complicated UTI patients you treat in a month? *

<10%

10-20%

21-40%

41-60%

> 60%

Any other

Out of total UTI cases, what is the percentage of recurrent UTI do you see in a month? *

10-20%

21-30%

31-40%

>40%

Any other

What is your preferred line of treatment for Uncomplicated UTI in adult patients? (Mention molecule name) *

1^st Line
2^nd Line
3^rd Line
Any other

What is your preferred line of treatment for Complicated UTI in adult patients? (Mention molecule name) *

1^st Line
2^nd Line
3^rd Line
Any other

In which case scenario/s, you decide to prescribe faropenem in UTI management? (Multiple options can be selected) *

High grade fever

Severe abdominal pain

Drug induced UTI (e.g., 2 inhibitors)

Resistant cases

Any other

When do you prefer faropenem in the management of different types of UTI? (Multiple options can be selected) *

Uncomplicated UTI

Complicated UTI

Recurrent UTI

Any other

What are the perceived advantages of faropenem over other antimicrobials as per your clinical experience? *

What percentage of recurrent UTI cases do you treat with faropenem? *

<10%

11-20%

21-40%

>40%

Any other

In what percentage of uncomplicated UTI patient, do you prefer to use faropenem? *

5-10%

11-20%

21-30%

> 30%

Any other

In what percentage of complicated UTI patient, do you prefer to use Faropenem? *

5-10%

11-20%

21-30%

> 30%

Any other

In your practice what percentage of complicated UTI patients require hospitalization? *

5-10%

11-20%

21-30%

> 30%

Any other

Which one is your preferred IV injectable antibiotic in UTI management and why? *

As per your clinical experience what are the advantages of faropenem as a step-down therapy after IV therapy in the management of UTI? *

What are the parameters on the basis of which you decide to switch UTI patient on I.V. antibiotic to oral antibiotic? *

How do you decide to terminate therapy with oral antibiotics after switching from I.V. antibiotics in UTI management? *

What is your clinical experience about step-down therapy with faropenem compared to step-down therapy with other antimicrobials in the management of UTI? *

After which IV antibiotic in UTI do you prefer to prescribe oral faropenem? (Multiple options can be selected) *

Ceftrioxone

Meropenem

Piperacillin-tazobactam

Cefoperazone Sulbactam

Amikacin

Trimethoprim-sulphamethoxazole

Any other

In what percentage of hospitalised UTI patients, do you prefer to prescribe faropenem as a stepdown therapy? *

<20%

21-40%

41-60%

>60%

Any other

Out of total UTI patients on faropenem in your practice, how many of them receive faropenem on OPD basis? *

10-20%

21-30%

31-40%

40-50%

>50%

Any other

On an average, how many SSTI cases do you treat per month? *

<10

10-20

21-40

> 40

Any other

What is your preferred line of antibiotic treatment for treating SSTI in adult patients? *

1^st Line
2^nd Line
3^rd Line
Any other

In what percentage of SSTI patient you prefer to use faropenem? *

5-10%

11-20%

21-30%

> 30%

Any other

When do you decide to prescribe faropenem in SSTI? (Multiple options can be selected) *

Deep seated infections

High grade fever

Resistant cases

Diabetic patients

Any other

What are the perceived advantages of faropenem as per your clinical experience in the management of SSTI? *

In which of the following conditions do you prefer to use faropenem? (Multiple options can be selected) *

Cellulitis

Abscess

Diabetic Foot ulcers

Wound infections

Post Operative infections

Any other

What percentage of SSTI patients’ needs hospitalization? *

<10%

11-20%

21-30%

>30%

Which one is your preferred IV injectable antibiotic in SSTI management and why? *

As per your clinical experience what are the advantages of faropenem as a step-down therapy after IV therapy in the management of SSTI? *

What is your clinical experience about step-down therapy with faropenem compared to step-down therapy with other antimicrobials in the management of SSTI? *

What are the parameters on the basis of which you decide to switch SSTI patient on I.V. antibiotic to oral antibiotic? *

How do you decide to terminate therapy with oral antibiotics after switching from I.V. antibiotics in SSTI management? *

After which IV antibiotic do you prefer to use oral faropenem in SSTI? (Multiple options can be selected) *

Amoxicillin / Clavulanic acid

Ceftrioxone

Meropenem

Piperacillin-tazobactam

Clindamycin

Linezolid

Any other

In what percentage of hospitalised SSTI patients, do you prefer to prescribe faropenem as a stepdown therapy? *

<20%

21-40%

41-60%

>60%

Any other

In how many SSTI patients you prescribe faropenem in your practice on OPD basis? *

<20%

21-40%

41-60%

>60%

Any other

What is your preferred duration of faropenem treatment in your clinical practice for UTI and SSTI? *

UTI – Duration of treatment
SSTI – Duration of treatment

What are the challenges of selecting and using faropenem for the management of bacterial infections? *